Use of Methylphenidate in Excessive Daytime Sleepiness in Alzheimer’s Patients Treated with Donepezil: Case Series

References

• Taragano FE, Allegri RF, Krupitzki H, et al. Mild behavioral impairment and risk of dementia: a prospective cohort study of 358 patients. J Clin Psychiatry. 2009;70:584–592. doi:10.4088/JCP.08m0418119323967
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Mielke MM, Appleby B, Oh E, Leoutsakos JM, Lyketsos CG. Neuropsychiatric symptoms in MCI subtypes: the importance of executive dysfunction. Int J Geriatr Psychiatry. 2011;26:364–372.20845402
   PubMed Web of Science ®Google Scholar
• Bidzan M, Bidzan L, Bidzan-Bluma I. Neuropsychiatric symptoms and faster progression of cognitive impairments as predictors of risk of conversion of mild cognitive impairment to dementia. Arch Med Sci. 2017;13(5):1168–1177. doi:10.5114/aoms.2017.6894328883859
   PubMed Web of Science ®Google Scholar
• Urrestarazu E, Iriarte J. Clinical management of sleep disturbances in Alzheimer’s disease: current and emerging strategies. Nat Sci Sleep. 2016;14(8):21–33. doi:10.2147/NSS.S76706
   Web of Science ®Google Scholar
• Sullivan SC, Richards KC. Predictors of circadian sleep-wake rhythm maintenance in elders with dementia. Aging Ment Health. 2004;8(2):143–152.14982719
   PubMed Web of Science ®Google Scholar
• McCurry SM, Vitiello MV, Gibbons LE, Logsdon RG, Teri L. Factors associated with caregiver reports of sleep disturbances in persons with dementia. Am J Geriatr Psychiatry. 2006;14(2):112–120. doi:10.1097/01.JGP.0000192499.25940.da16473975
   PubMed Web of Science ®Google Scholar
• Autret A, Lucas B, Mondon K, et al. Sleep and brain lesions: a critical review of the literature and additional new cases. Neurophysiol Clin. 2001;31(6):356–375. doi:10.1016/S0987-7053(01)00282-911810986
   PubMed Web of Science ®Google Scholar
• Kitabayashi Y, Ueda H, Tsuchida H, Yamashita T, Narumoto J, Fukui K. (2006). Donepezil-induced nightmares in mild cognitive impairment. Psychiatry Clin Neurosci. 2006;60(1):123–124. doi:10.1111/j.1440-1819.2006.01474.x16472374
   PubMed Web of Science ®Google Scholar
• Singer M, Romero B, Koenig E, Förstl H, Brunner H. (2005). Nightmares in patients with Alzheimer’s disease caused by donepezil. Therapeutic effect depends on the time of intake. Nervenarzt. 2005;76(9):1127–1129. doi:10.1007/s00115-004-1856-715630600
   PubMed Web of Science ®Google Scholar
• Cooke JR, Loredo JS, Liu L, et al. Acetylcholinesterase inhibitors and sleep architecture in patients with Alzheimer’s disease. Drugs Aging. 2006;23(6):503–511. doi:10.2165/00002512-200623060-0000516872233
   PubMed Web of Science ®Google Scholar
• Moraes Wdos S, Poyares DR, Guilleminault C, Ramos LR, Bertolucci PH, Tufik S. The effect of donepezil on sleep and REM sleep EEG in patients with Alzheimer disease: a double-blind placebo-controlled study. Sleep. 2006;29(2):199–205. doi:10.1093/sleep/29.2.19916494088
   PubMed Web of Science ®Google Scholar
• Liston DR, Nielsen JA, Villalobos A, et al. Pharmacology of selective acetylcholinesterase inhibitors: implications for use in Alzheimer’s disease. Eur J Pharmacol. 2004;486(1):9–17. doi:10.1016/j.ejphar.2003.11.08014751402
   PubMed Web of Science ®Google Scholar
• Mungas D, Marshall SC, Weldon M, Haan M, Reed BR. Age and education correction of mini-mental state examination for english and Spanish-speaking elderly. Neurology. 1996;46(3):700–706. doi:10.1212/WNL.46.3.7008618670
   PubMed Web of Science ®Google Scholar
• Mizuno S, Kameda A, Inagaki T, Horiguchi J. Effects of donepezil on Alzheimer’s disease: the relationship between cognitive function and rapid eye movement sleep. Psychiatry Clin Neurosci. 2004;58:660–665. doi:10.1111/j.1440-1819.2004.01317.x15601392
   PubMed Web of Science ®Google Scholar
• Chin WC, Huang YS, Chou YH, et al. Subjective and objective assessments of sleep problems in children with attention deficit/hyperactivity disorder and the effects of methylphenidate treatment. Biomed J. 2018;41(6):356–363. doi:10.1016/j.bj.2018.10.00430709577
   PubMed Web of Science ®Google Scholar
• Kittur S, Hauser P. Improvement of sleep and behavior by methylphenidate in Alzheimer’s disease. Am J Psychiatry. 1999;156(7):1116–1117.10401468
   PubMed Web of Science ®Google Scholar
• Sobanski E, Schredl M, Kettler N, Alm B. Sleep in Adults with Attention Deficit Hyperactivity Disorder (ADHD) before and during treatment with methylphenidate: a controlled polysomnographic study. Sleep. 2008;31(3):375–381. doi:10.1093/sleep/31.3.37518363314
   PubMed Web of Science ®Google Scholar
• Alkhodier H, Wang H, Sun H, et al. Oral Health in Attention Deficit Hyperactivity Disorder (ADHD). J Ora Med. 2018;2:1–2.
   Google Scholar
• Konrad-Bindl DS, Gresser U, Richartz BM. Changes in behavior as side effects in methylphenidate treatment: review of the literature. Neuropsychiatr Dis Treat. 2016;12:2635–2647. doi:10.2147/NDT.S11418527789952
   PubMed Web of Science ®Google Scholar
• Scoralick FM, Camargos EF, Freitas MP, Nóbrega OT. Outpatient treatment of sleep disorders in Alzheimer patients. Einstein. 2015;13(3):430–434. doi:10.1590/S1679-45082015RW302125946052
   PubMedGoogle Scholar
• Weldemichael DA, Grossberg GT. Circadian rhythm disturbances in patients with alzheimer’s disease: a review. Int J Alzheimers Dis. 2010;716453. doi:10.4061/2010/71645320862344
   PubMedGoogle Scholar
• Gehrman P, Marler M, Martin JL, Shochat T, Corey-Bloom J, Ancoli-Israel S. The timing of activity rhythms in patients with dementia is related to survival. J Gerontol Series A. 2004;59(10):M1050–M1055. doi:10.1093/gerona/59.10.M1050
   PubMed Web of Science ®Google Scholar
• Mignot EJM. A practical guide to the therapy of narcolepsy and hypersomnia syndromes. Neurotherapeutics. 2012;9(4):739–752. doi:10.1007/s13311-012-0150-923065655
   PubMed Web of Science ®Google Scholar
• Padala PR, Padala KP, Lensing SY, et al. Methylphenidate for apathy in community-dwelling older veterans with mild alzheimer’s disease: a double-blind, randomized, placebo-controlled trial. Am J Psychiatry. 2018;175(2):159–168. doi:10.1176/appi.ajp.2017.1703031628945120
   PubMed Web of Science ®Google Scholar
• Ruthirakuhan MT, Herrmann N, Abraham EH, Chan S, Lanctôt KL. Pharmacological interventions for apathy in Alzheimer’s disease. Cochrane Database Syst Rev. 2018;4(5):CD012197. doi:10.1002/14651858.CD012197
   Google Scholar
• Padala PR, Burke WJ, Shostrom VK, et al. Methylphenidate for apathy and functional status in dementia of the Alzheimer type. Am J Geriatr Psychiatry. 2010;18(4):371–374. doi:10.1097/JGP.0b013e3181cabcf620220576
   PubMed Web of Science ®Google Scholar
• Rosenberg PB, Lanctôt KL, Drye LT, et al. Safety and efficacy of methylphenidate for apathy in Alzheimer’s disease: a randomized, placebo-controlled trial. J Clin Psychiatry. 2013;74(8):810–816. doi:10.4088/JCP.12m0809924021498
   PubMed Web of Science ®Google Scholar
• Lanctôt KL, Chau SA, Herrmann N, et al. Effect of methylphenidate on attention in apathetic AD patients in a randomized, placebo controlled trial. Int Psychogeriatr. 2014;26(2):239–246. doi:10.1017/S104161021300176224169147
   PubMed Web of Science ®Google Scholar